公开(公告)号：US20240358687A1

公开(公告)日：2024-10-31

申请号：US18651929

申请日：2024-05-01

Applicant: CALLIDITAS THERAPEUTICS SUISSE SA ,  UNIVERSITY OF SOUTHAMPTON

Inventor： Philippe WIESEL ,  Freddy HEITZ ,  Gareth THOMAS ,  Christopher HANLEY ,  Kristy FORD

IPC: A61K31/437 ,  A61K31/4025 ,  A61K31/5377 ,  A61K35/17 ,  A61K38/19 ,  A61K39/00 ,  A61K39/245 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/437 ,  A61K31/4025 ,  A61K31/5377 ,  A61K35/17 ,  A61K38/191 ,  A61K39/245 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/507

Abstract: The present invention is related to compounds, methods, compositions and uses that are able to restore responsiveness to immunotherapy, in particular immune check point inhibitors or anti-cancer vaccine or to anti-angiogenesis treatment.

公开(公告)号：US20220233666A1

公开(公告)日：2022-07-28

申请号：US17264469

申请日：2020-10-19

Applicant: University of Southampton ,  Cancer Research Malaysia

Inventor： Natalia SAVELYEVA ,  Gareth THOMAS ,  Christian OTTENSMEIER ,  Chuan WANG ,  Sok Ching CHEONG ,  Kue Peng LIM

IPC: A61K39/00 ,  A61P35/00

Abstract: The present invention relates to nucleic acid vaccines which encode at least a MAGED4B protein, for use in the treatment of cancer in particular. Synergistic combinations with other anti-cancer agents are described, particularly immune checkpoint inhibitors. The cancer vaccine may further comprise an immunologically active fragment to enhance the immune response, and an additional cancer antigen, such as FJX1. Particular combination therapies of interest include immunotherapies, radiotherapy, targeted therapies and chemotherapies.